What the NEIGHBORS say

Anonymous,

10.1182/blood.2020010529 Hospitalized COVID-19 patients are at risk of both venous thromboembolism (VTE) and arterial thromboembolism (ATE), and it appears that mortality in these patients may be due to thrombotic events even more commonly than has previously been appreciated. One limitation of this study is the relatively small subgroup receiving postdischarge thromboprophylaxis, but the striking findings argue strongly for randomized trials of safety and efficacy of extended postdischarge thromboprophylaxis in severely ill COVID-19 patients. B cell-activating factor modulates the factor VIII immune response in hemophilia A. I J Clin Invest i . 2021;131(8):e142906. https://doi.org/10.1172/JCI142906 Neutralizing anti-factor VIII (FVIII) antibodies develop in ~30% of severe hemophilia A patients, most often within the first 50 exposures to their replacement therapy. [Extracted from the article] Copyright of Journal of Thrombosis & Haemostasis is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)